Addressing Challenges and New Developments in Endometriosis Clinical Research

Over the last decade, an increasing number of drug development sponsors have conducted endometriosis clinical trials to explore more specific therapeutic targeting approaches for this chronic disease. While these changes are promising to address ongoing unmet medical needs, clinical trials continue to face many hurdles due to challenges with diagnosing patients, navigating restrictive regulatory guidelines and designing appropriate trials.

Register for this educational webinar, which will cover several aspects of endometriosis drug development through the perspectives of three specialists. From the translational research gaps to current clinical trial practices, trial design and enrollment, participants will gain a greater understanding of both the medical and operational considerations for supporting these trials, as well as insights on the patient journey in the industry’s quest to create safer and more efficacious treatments.

Speakers

Friedrich Wieser, MD, Medical Director, Labcorp Drug Development

Dr. Wieser is a trained gynecologist with a fellowship in reproductive medicine and over 20 years of clinical research experience in Women’s Health in academia and pharmaceutical industry settings. Dr. Wieser accomplished the highest academic qualification for studies in endometriosis at the Medical University of Vienna.  He has led NIH-funded investigations on endometriosis and conducted studies on menopause, infertility, and gynecologic medical devices.  He held a leadership role in Women’s Health at Merck KGaA Healthcare, leading drug development and early stage innovation in the field of Human Reproduction prior joining Labcorp in the Women’s Health group.

Message Presenter

Hugh Taylor, MD, Professor of Women’s Health and chair of the Department of Obstetrics, Gynecology and Reproductive Science, Yale School of Medicine

Dr. Taylor is a board-certified specialist in obstetrics/gynecology and in reproductive endocrinology. He has been a principal investigator on 15 NIH grants, and site PI or co-investigator on numerous additional NIH-funded projects. His clinical research centers on implantation, endometriosis and menopause. Dr. Taylor is also a professor of molecular, cellular and developmental biology at Yale University, where his basic science research focuses on uterine development and the regulation of developmental gene expression by sex steroids, endocrine disruption and on stem cells. Dr. Taylor has published more than 400 articles in leading medical journals and currently serves as the American Society for Reproductive Medicine (ASRM) president.

Message Presenter

Mary Furmato, CPM, Senior Director, Strategy & Planning, Neurology, Ophthalmology & Women’s Health, Labcorp Drug Development

Mary Furmato has over 30 years with Labcorp Drug Development, where she has developed a wide range of experience in managing and monitoring U.S. and global studies in both diagnostic and device studies within broad therapeutic areas including cardiovascular, infectious disease, general medicine, neuroscience, ophthalmology and women’s health. Her experience conducting women’s health Phase II-IV global studies includes endometriosis, contraception, obesity and osteoporosis. Ms. Furmato’s focus is on fostering strong client relationships, providing guidance and mentoring for members of the study team and specializing in coordination of strategy development for successful study delivery.

Message Presenter